The molecular signaling pathway EGFR-STAT1 is key for driving fibrosis (scarring) in scleroderma, according to a new study. The findings suggest that treatments designed to inhibit this pathway could be used to help mitigate fibrosis in scleroderma and other disorders that are characterized by excessive scarring. The study, “…
News
Limited hand function makes everyday tasks, work, and hobbies difficult for adults with systemic sclerosis (SSc), according to an interview-based study. The loss of hand mobility and strength also affects emotional health and social life. Patients said tasks requiring fine motor skills — such as typing or writing —…
A CAR T-cell therapy being developed by Bristol Myers Squibb eased skin thickness and improved lung function in people with systemic sclerosis (SSc), early trial data showed. These initial results for the treatment, BMS-986353, come from the Phase 1 Breakfree-1 clinical trial (NCT05869955), which is testing the therapy’s…
Milk-derived extracellular vesicles — very small, natural particles from cow’s milk — were shown to safely reduce inflammation and scarring in a mouse model of systemic sclerosis (SSc). Because these vesicles carry molecules that can protect and help tissue repair itself, they “have attracted much attention due to their…
In people with diffuse cutaneous systemic sclerosis (dcSSc), certain skin features, including levels of specific molecules and cells, depend on disease duration, a study finds. These features, combined with disease duration, allowed researchers to predict patients’ response to mycophenolate mofetil (MMF), an immunosuppressive therapy commonly used for dcSSc. These…
More than a third of adults with systemic sclerosis (SSc) who develop interstitial lung disease (ILD) see their condition progress, and those who reported increasing shortness of breath in the past month had a higher risk of death — even if their breathing tests have not declined — an…
Researchers in China have identified five genes — COL1A2, COL3A1, COL15A1, THY-1, and CCL19 — that may play a key role in lung complications associated with systemic sclerosis (SSc), according to a study. Using bioinformatics analyses of patient tissue samples, the team found that these genes were consistently overactive…
People with scleroderma may have slightly elevated symptoms of anxiety compared to the general population, particularly those in specific sociodemographic subgroups, an international study reported. Researchers found that several demographic features, such as being younger or non-white, as well as disease features, including gastrointestinal symptoms, were associated with higher…
Increasing levels of self-reactive antibodies in the bloodstream after the start of treatment are associated with the progression of systemic sclerosis (SSc), according to recent research. “We hypothesize that rising antibody [levels] during treatment may reflect ongoing immune activation, insufficient therapeutic response, or impending flare, whereas decreasing [levels] may…
The presence and severity of interstitial lung disease in people with systemic sclerosis (SSc) are associated with a specific combination of bacteria in the gut, a study suggests. “These species or their metabolic products may influence ILD [disease processes] and represent novel treatment targets,” the study’s researchers wrote. The…
Recent Posts
- New lab findings support development of stem cell treatments for SSc-ILD
- Type of immune cell may be key driver of scleroderma scarring: Study
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression